# BioInvent International

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/bioinventinternational).

## Overview

BioInvent International is a biotechnology company focused on developing novel immuno-modulatory antibodies for cancer therapy. The company is advancing its clinical programs with a strategic focus on its lead assets, BI-1206 and BI-1808, which show promise in treating liquid and solid cancers. BioInvent collaborates with pharmaceutical companies and academic institutions to enhance its research capabilities and expand its clinical pipeline. The company is headquartered in Sweden and operates globally, leveraging partnerships to drive innovation and value creation in oncology treatments.

## Products & services

• BI-1206 for non-small cell lung cancer and uveal melanoma
• BI-1808 for solid tumors
• Oncolytic virus BT-001 in collaboration with Transgene
• Outlicensed projects including Mezagitamab (TAK-079)
• Production of antibodies for clinical studies

- **Immuno-oncology Therapies** (50%) — Includes BI-1206 and BI-1808 for cancer treatment
- **Oncolytic Viruses** (20%) — Includes BT-001 developed with Transgene
- **Outlicensed Projects** (15%) — Projects licensed to other companies for development
- **Antibody Production** (15%) — Production of antibodies for clinical studies

- BI-1206 for non-small cell lung cancer and uveal melanoma
- BI-1808 for solid tumors
- Oncolytic virus BT-001 in collaboration with Transgene
- Outlicensed projects including Mezagitamab (TAK-079)
- Production of antibodies for clinical studies

## Customers

BioInvent's customer base includes pharmaceutical companies and academic institutions engaged in oncology research and development. The company collaborates with leading pharmaceutical firms such as Takeda and AstraZeneca to advance its clinical assets. Academic partnerships allow BioInvent to access cutting-edge scientific expertise and potentially acquire new assets for development. The company's outlicensed projects provide opportunities for milestone payments and royalties, appealing to partners seeking innovative cancer therapies.

- **Pharmaceutical Companies** (primary) — Buy novel cancer therapies and collaborate on clinical assets
- **Academic Institutions** (secondary) — Collaborate on research and provide scientific expertise
- **Outlicensing Partners** (emerging) — Engage in projects with potential for milestone payments

- Pharmaceutical companies seeking novel cancer therapies
- Academic institutions for collaborative research
- Partners interested in outlicensed projects for milestone payments
- Companies requiring antibody production for clinical studies

## Geography

BioInvent is headquartered in Sweden and operates globally, with significant collaborations in Europe and the USA. The company's strategic partnerships with pharmaceutical giants like AstraZeneca and Takeda extend its reach in key markets. BioInvent's antibody production facilities are located in Sweden, supporting its clinical studies worldwide. The company's geographic presence is crucial for accessing diverse markets and leveraging international expertise in oncology research.

- Headquartered in Sweden with global operations
- Collaborations in Europe and the USA with pharmaceutical giants
- Antibody production facilities located in Sweden
- Strategic presence in key oncology research markets

## Strategy

BioInvent's strategic focus is on accelerating the development of its lead clinical programs, BI-1206 and BI-1808, to maximize therapeutic impact and shareholder value. The company has paused less promising projects to concentrate resources on these assets, which have shown strong clinical signals. BioInvent aims to enhance value creation through strategic collaborations and partnerships. The company's disciplined approach is designed to support future growth while maintaining core research capabilities.

- **Accelerate Lead Programs** (medium-term) — To maximize therapeutic impact and shareholder value
- **Strategic Collaborations** (long-term) — To enhance value creation and expand clinical pipeline

- Accelerating development of lead programs BI-1206 and BI-1808
- Pausing less promising projects to focus resources
- Enhancing value creation through strategic collaborations
- Maintaining core research capabilities for future growth

## Risks

BioInvent faces several risks, including the inherent uncertainties of clinical trials and regulatory approvals. The company's reliance on strategic partnerships exposes it to risks related to partner performance and collaboration outcomes. Financial risks include potential fluctuations in revenue from outlicensed projects and antibody production. Industry-specific risks such as changes in healthcare regulations and competitive pressures also pose challenges. BioInvent must navigate these risks to achieve its strategic objectives and maintain its competitive position.

- **Clinical Trial Uncertainty** [critical] — Potential delays or failures in trials
- **Partnership Dependency** [high] — Reliance on partner performance for project success
- **Revenue Fluctuation** [medium] — Variability in income from outlicensed projects

- Uncertainties of clinical trials and regulatory approvals
- Reliance on strategic partnerships and partner performance
- Revenue fluctuations from outlicensed projects
- Changes in healthcare regulations and competitive pressures

## Accounting

BioInvent's financial statements are prepared in accordance with IAS 34, with no material impact from recent changes in IFRS standards. Revenue recognition from outlicensed projects and antibody production can lead to variability in reported income. The company's financial performance is subject to fluctuations due to milestone payments and royalties from collaborations. Investors should consider the impact of strategic shifts on financial results, as well as the company's reliance on external partnerships for revenue generation.

- **Revenue Recognition** — medium
- **Milestone Payments** — high

- Prepared in accordance with IAS 34
- Revenue recognition from outlicensed projects affects income variability
- Milestone payments and royalties impact financial performance
- Strategic shifts influence financial results

---

*Last updated: 2026-08-11T04:04:51.245443+00:00*